 | |
| Clinical data | |
|---|---|
| Other names | (3E)-3-({[(2S)-2-Amino-3-methylbutanoyl]oxy}imino)pregn-4-en-20-one |
| Drug class | Progestogen;Neurosteroid |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H40N2O3 |
| Molar mass | 428.617 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
P1-185, also known asprogesterone 3-O-(L-valine)-E-oxime or aspregn-4-ene-3,20-dione 3-O-(L-valine)-E-oxime, is asyntheticprogestogen andneurosteroid and anoximeesteranalogue andprodrug ofprogesterone (and by extension ofallopregnanolone).[1][2] It was developed as an improvedwater-soluble version of progesterone such that it could be formulated as anaqueous preparation and easily and rapidly administeredintravenously as a potential therapy fortraumatic brain injury.[1][2] However, thechemical synthesis of P1-185 was described as somewhat challenging, so oxime conjugates of progesterone of the C20 instead of C3 position, such asEIDD-1723 andEIDD-036, have since been developed.[2][3][4]
Media related toP1-185 at Wikimedia Commons | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
